Synagis, Porges says, could still have more room for growth on price increases and population growth.
FORBES: Is There Hidden Value In MedImmune?
The all-cash offer for MedImmune gives AstraZeneca the rights to Synagis, a preventive for respiratory infections in premature infants, and a follow-up drug that is still in development.
FORBES: Magazine Article
应用推荐
模块上移
模块下移
不移动